Business Description
BCAL Diagnostics Ltd
ISIN : AU0000160921
Share Class Description:
ASX:BDX: Ordinary SharesDescription
BCAL Diagnostics Ltd is an Australian health care company engaged in early cancer detection. BCAL launched its first test, BREASTESTplus, as a rule-out test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women. BCAL holds an exclusive license with ClearNote Health Inc., a U.S-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | -0.11 | |||||
Debt-to-Equity | -8.37 | |||||
Debt-to-EBITDA | -1.09 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -7.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.8 | |||||
3-Year EPS without NRI Growth Rate | 5.9 | |||||
3-Year FCF Growth Rate | 14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 37.46 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.02 | |||||
9-Day RSI | 65.05 | |||||
14-Day RSI | 57.75 | |||||
3-1 Month Momentum % | 1.35 | |||||
6-1 Month Momentum % | -37.5 | |||||
12-1 Month Momentum % | 22.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.36 | |||||
Quick Ratio | 1.36 | |||||
Cash Ratio | 0.53 | |||||
Days Sales Outstanding | 163.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.2 | |||||
Shareholder Yield % | -13.12 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5132.24 | |||||
Net Margin % | -4027.87 | |||||
EBITDA Margin % | -3465.03 | |||||
FCF Margin % | -3616.94 | |||||
OCF Margin % | -3366.12 | |||||
ROE % | -280.16 | |||||
ROA % | -89.37 | |||||
ROIC % | -212.84 | |||||
3-Year ROIIC % | -62.17 | |||||
ROC (Joel Greenblatt) % | -232.48 | |||||
ROCE % | -122.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -4.36 | |||||
EV-to-EBITDA | -4.85 | |||||
EV-to-Revenue | 168.13 | |||||
EV-to-FCF | -4.65 | |||||
Earnings Yield (Greenblatt) % | -22.94 | |||||
FCF Yield % | -26.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BCAL Diagnostics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.183 | ||
| EPS (TTM) (A$) | -0.02 | ||
| Beta | 0.5022 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 54.18 | ||
| 14-Day RSI | 57.75 | ||
| 14-Day ATR (A$) | 0.003832 | ||
| 20-Day SMA (A$) | 0.06025 | ||
| 12-1 Month Momentum % | 22.95 | ||
| 52-Week Range (A$) | 0.052 - 0.155 | ||
| Shares Outstanding (Mil) | 368.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BCAL Diagnostics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BCAL Diagnostics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BCAL Diagnostics Ltd Frequently Asked Questions
What is BCAL Diagnostics Ltd(ASX:BDX)'s stock price today?
The current price of ASX:BDX is A$0.07. The 52 week high of ASX:BDX is A$0.16 and 52 week low is A$0.05.
When is next earnings date of BCAL Diagnostics Ltd(ASX:BDX)?
The next earnings date of BCAL Diagnostics Ltd(ASX:BDX) is .
Does BCAL Diagnostics Ltd(ASX:BDX) pay dividends? If so, how much?
BCAL Diagnostics Ltd(ASX:BDX) does not pay dividend.
Press Release
Articles on BCAL Diagnostics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers